New hopes for Mexico
What will be the future of healthcare under the country's new administration?
In December 2018 the new Mexican President, Andres Manuel Lopez Obrador came into office after a landslide victory of over 65% of the votes (more than 30 billion voters). López Obrador was a former Mexico City mayor and has been a major political figure for over twenty years. Widely regarded as both a populist and nationalist, his ideology is to end poverty and improve the lives of his people by fighting corruption and increasing austerity within the government.
Fast and furious: What will the fast tracking of approvals for key drugs mean for China's pharma market?
China has long been a magnet for pharmaceutical multinationals looking to offset flattening growth in established markets
It offers rapid economic development, a population of around 1.4 billion with limited access to cutting-edge medicine, and changing lifestyles that have raised health expectations. Expanded access to state-funded healthcare, population aging and a growing burden of chronic disease are creating new opportunities for innovative drugs alongside low-cost generics.
Navigating new frontiers: Ways to find space in the future RA market
In partnership with pharmaphorum
Rheumatoid arthritis (RA) has been a major growth driver for the pharmaceutical industry over the last 15 years, led by AbbVie’s blockbuster anti-TNF inhibitor treatment Humira (adalimumab).
Could you nudge your brand to success using behavioural economic theory?
With behavioural economics theory becoming more widely adopted, especially within the market research sector, terms such as ‘nudging’ have started to enter our vocabulary. Director Anthony Greenwood discusses what ‘nudging’ means for market research and the role it could play in marketing pharma and med-tech brands.
How we used behavioural economic theory to reveal fresh insights into patient compliance
Our client currently has a product for a chronic rare disease which has seen an initial successful uptake. HCPs appear to support the product and are actively prescribing it to suitable patients.
However, sales data suggests that repeat prescriptions drastically reduce after the first 3-6 months. Although the product has a known SE profile, our client believes that this can be well managed and controlled.